Health Condition 1: null- Patients with common warts (Verruca vulgaris)
Conditions
Interventions
Intervention1: MMR Vaccine: 0.25 ml MMR vaccine (Tresivac) marketed by Serum Institute of India Ltd will be injected intralesionally, every two weekly for 5 doses.
Control Intervention1: Normal saline
Sponsors
Nil
Eligibility
Inclusion criteria
Inclusion criteria: All consecutive patients and controls of both genders clinically diagnosed with common warts who have not received treatment for their warts in preceding one month
Exclusion criteria
Exclusion criteria: Pregnant and lactating women, children <12 years, patients with apparent infection or immunosuppression, asthma, allergic skin disorders, meningitis or convulsions
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Resolution of all warts including distant untreated warts, and adverse effectsTimepoint: follow up every 2 weeks at the time of intervention up to 5 injections and then every month for 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Relapse and Adverse effectsTimepoint: follow up every 2 weeks at the time of intervention up to 5 injections and then every month for 6 months | — |
Countries
India
Contacts
Public ContactDr Vikram Mahajan
Govt Medical College
Outcome results
None listed